Pular para o conteúdo principal
Ranking Invest

ANAB - AnaptysBio, Inc.

Segmento: HealthcareAnaptysBio, Inc., a clinical stage biotechnology company, engages in developing therapeutic product candidates for inflammation and immuno-oncology indications. Its products include Imsidolimab, an antibody that inhibits the interleukin-36 receptor (IL-36R) for the treatment of various dermatological inflammatory diseases; Rosnilimab, an anti-PD-1 agonist antibody program designed to augment PD-1 signaling through rosnilimab treatment to suppress T-cell driven human inflammatory diseases; and ANB032, an anti-BTLA modulator antibody applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. and Bristol-Myers Squibb; and license agreements with United Kingdom Research and Innovation, as well as Millipore Corporation. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.

Análise Ranking Invest

Valuation estimado
-$ 394.09 Mi
Valor de Mercado
$ 1.59 Bi
Desconto (AV)-504.6%
IVR
-0.25A companhia vale -0,25 vezes o seu valor de mercado atual de acordo com a estimativa do Ranking Invest.
IVR2
-0.27O valuation alternativo equivale a -27% do valor de mercado da companhia.
MLL
-0.27O lucro líquido dos controladores em 16 trimestres equivale a -27% do valor de mercado.
Último Balanço Atualizado: 1T2026

O Ranking Invest utiliza metodologia própria baseada em dados financeiros objetivos, considerando patrimônio, lucratividade e endividamento para estimar o valuation das empresas.

Dados da Empresa

Patrimônio Líquido

$ 12.75 Mi

Dívida Líquida

-$ 248.47 Mi

L4T

-$ 26.79 Mi

MM4T

-78.70%

Indicadores Básicos

ROE

-210.14%

Índices de Previsibilidade

Receita Líquida

G0.86

Lucro

C0.31

Margem

D0.84

Índices de Tendência

Receita Líquida

B8.72

Lucro

C3.06

Margem

A9.12

Índices de Endividamento

DIV/PAT

-19.49

DIV/L4T

9.28

Dívidas
Cotação
Gráfico Lucro/Receita Líquida X TrimestrePor padrão são exibidos os últimos 16 trimestres; quando houver mais trimestres disponíveis, use o botão junto à tabela de resultados para expandir o histórico.